Navigation Links
Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients
Date:3/15/2011

Montreal, March 15, 2011 The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

CER-001 is an innovative complex of recombinant human ApoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL, which is believed to be protective against atherosclerosis. It is hoped that CER-001 will further reduce cardiovascular events in high-risk patients by promoting removal of cholesterol from the vessel wall.

The double-blind, randomized, placebo-controlled, safety and efficacy study will assess the ability of CER-001 to regress coronary atherosclerotic plaque as measured by intravascular ultrasound (IVUS). The study will include over 500 patients at fifty centers in the US, Canada and Europe, and will evaluate three different dose levels given in six weekly intravenous infusions.

The study is being done in collaboration with the Global Atherothrombotic Investigative Network (GAIN). Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, is serving as the principal investigator. "We are excited to be conducting the CHI-SQUARE study, which aims to show benefits of CER-001 on atherosclerotic plaque following a short course of therapy." said Dr. Tardif. "This is the largest IVUS study conducted with a pre-beta HDL mimetic, and represents a potential new treatment paradigm to reduce the burden of atherosclerosis."

Pre-beta HDL is believed to protect against cardiovascular disease by removing cholesterol and other lipids from tissues including the arterial wall and transporting them to the liver for elimination. The aim for the clinical use of a recombinant ApoA-I HDL mimetic is to stimulate cholesterol removal in a process known as reverse lipid transport.

"Following the excellent safety and tolerability Phase I results with CER-001, this trial will evaluate the efficacy in ACS patients," said Jean-Louis Dasseux, CEO of Cerenis. "The potential of HDL therapy is well recognized and CER-001, as a first in class pre-beta HDL mimetic, could have great therapeutic value to patients with ACS."


'/>"/>

Contact: Julie Chevrette
julie.chevrette@icm-mhi.org
514-376-3330 x2641
Montreal Heart Institute
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
3. MSU researcher links potentially deadly infection, frequent cow exposure
4. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
5. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
6. Morgan & Morgan's Personal Injury Attorneys Provide Information About Yaz, Yasmin, and Ocella Injuries and Potential Health Risks
7. International Medical Corps Emergency Response Team on Standby as It Monitors Situation in Chile and Potential Tsunami Areas
8. New testing method hints at garlics cancer-fighting potential
9. Research identifies potential new use for cancer treatment
10. Midroog Ltd., an Affiliate of Moodys Investors Services, Rates Potential new Debt of Elbit Imaging
11. Innovative Service Revolutionizes How Businesses Research Product Sales Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Sunny Isles Beach is in the ... flooding, or loss of utility services. The time for planning is now, before a ... have a plan in place. Families should follow the recommendations of the Miami-Dade County ...
(Date:5/31/2016)... , ... May 31, 2016 , ... According to recent ... States, and more than 100,000 physical therapy clinics. Each physical therapy professional and ... of clients. At the same time, staying afloat in a competitive industry is also ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... Pardoe, FDAI, DAHC, CDC, has joined the Fire Door Solutions’ team. Keith ... and fire door and frame in-field re-labeling. He will be instrumental in ...
(Date:5/31/2016)... ... ... More than 80 representatives of the Hepatitis B Foundation , Hepatitis C ... event on National Hepatitis Testing Day outside of Philadelphia City Hall to raise awareness ... liver cancer. , Foundation leaders and the citywide coalition they created, Hep B United ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical Center ... information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and in ... organizations in the exchange. SJMC’s membership in the health information exchange underscores the ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016 , ... demand for its Patient Status Engine wireless patient monitoring platform, ... , Germany , Scotland ... The company,s 2 nd generation system, launched earlier this year, ... the world , , This new technology ...
(Date:5/30/2016)... May 30, 2016 ... "Healthcare Biometrics Market by Technology (Single-factor (Fingerprint, ... Multimodal), Application (Workforce Management), End User (Hospitals, ... published by MarketsandMarkets, the market is projected ... from USD 1,182.6 Million by 2016, at ...
(Date:5/30/2016)... 2016 - DCGI grants limited approval to ... disease - Stempeucel® becomes 5th off-the-shelf Stem cell product ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is ... and Globally - Prevalence of Buerger,s Disease is estimated ... per 10,000 persons in the European Community & USA ...
Breaking Medicine Technology: